Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|March 10, 2022

Curia Enters Cooperative Agreement with US Government to Expand Sterile Fill/Finish Capability

Curia and the US government have entered into a cooperative agreement to expand fill/finish capability for injectable medicines.

Curia, formerly AMRI, announced on March 9, 2022 that it is entering a cooperative agreement with the US government to expand and advance fill/finish capabilities for injectable medicines. The groups of the US government involved in the agreement include the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR); the Department of Defense Joint Program Executive Office or Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND); and the US Army Contracting Command.

The agreement will focus on funding to add a new high-speed fill/finish vial line, which includes biosafety level 2 (BSL-2) containment. Curia is also supporting smaller batch advanced therapies with two lyophilizers for the high-speed fill/finish line and an isolated flexible filling line for vials, syringes, and cartridges, all of which are self-funded.

The expansion will be housed at Curia’s Albuquerque, NM facility, which already supports the supply of various treatments and vaccines for cancer, cardiovascular, auto-immune, infectious, and rare diseases. The facility also is home to Curia’s “Sterile University,” a training program focused on simulating a sterile manufacturing environment for employees to develop skills that improve safety, efficacy, and accuracy in the workplace.

“This agreement assures our ability to meet urgent demands for the supply of critical medicines well into the future,” said John Ratliff, chairman and CEO of Curia, in a press release. “Scientific advances including biologics and vaccines require injectable formulations. The fill-finish of this type of product demands specialized expertise and equipment. Our investments in Curia’s Albuquerque facility have already increased capacity and added to our talented team in New Mexico. This agreement not only secures our continued contribution to the nation’s pandemic response plans, it also enables us to meet the need to deliver life-changing life science to patients into the future.”

Source: Curia

Related to this article

View more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more